SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

C4 Therapeutics to present new biomarker data for cemsidomide plus dexamethasone

C4 Therapeutics said it will present new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd IMS Annual Meeting.

CCCC
SquawkNews Desk

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories

Microsoft Says Consumer Services Recovered, Enterprise Recovery Ongoing Microsoft said its consumer products services had fully recovered at 4:10 p.m. UTC Friday, while Microsoft 365 enterprise services were seeing some sustained recovery. The company M impact | EQUITY | Nov 14, 2026, 05:32 AM UTC Microsoft Says Consumer Products Services Recovered Microsoft said its consumer products services had fully recovered, while Microsoft 365 enterprise services were seeing a sustained recovery. M impact | EQUITY | Nov 14, 2026, 05:17 AM UTC Microsoft restores consumer product services after outage Microsoft said its consumer product services have been restored; other services are not included in the update. M impact | EQUITY | Nov 14, 2026, 05:10 AM UTC Microsoft Outlook Begins Returning After Global Microsoft 365 Disruption Microsoft said it was working to restore email access after a global Microsoft 365 disruption. Industry executives warned of risks from dependence on a single technology provider. M impact | EQUITY | Nov 14, 2026, 04:31 AM UTC Tesla sells Cybercab to first private customers Reuters reports Tesla is offering its Cybercab to its first private customers. M impact | EQUITY | Nov 14, 2026, 04:23 AM UTC Microsoft says affected services fully recovered L impact | EQUITY | Nov 14, 2026, 04:14 AM UTC